eligibility_summary
Eligible: Adults (≥18) with histologically confirmed metastatic or recurrent breast cancer (TNBC, HER2+, and/or hormone receptor–positive). Must have received an antibody–drug conjugate at any treatment line and at least one cycle of trastuzumab deruxtecan (T-DXd) and/or sacituzumab govitecan (SG). No specified exclusion criteria.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational real-world study of two antibody–drug conjugates (ADCs) in pretreated advanced/metastatic breast cancer. 1) Trastuzumab deruxtecan (T-DXd): a HER2-targeting humanized monoclonal antibody linked via a cleavable linker to the topoisomerase I inhibitor deruxtecan (DXd). Mechanism: binds HER2 on tumor cells, internalizes, releases DXd causing DNA damage, supports bystander killing. Targets: HER2-expressing (including HER2-low) breast cancer cells, topoisomerase I pathway. 2) Sacituzumab govitecan (SG): a TROP-2–targeting humanized monoclonal antibody linked to SN-38 (topoisomerase I inhibitor) via a hydrolyzable linker. Mechanism: binds TROP-2, internalizes and can release SN-38 extracellularly, inducing DNA damage with bystander effect. Targets: TROP-2–positive tumor cells (notably TNBC), topoisomerase I pathway.